Table 2 Predicted marginal means (95% confidence intervals, CI), by responder group, for all outcome measures at baseline and at week 52

DAS28-ESR

5.1 (4.9, 5.4)*

6.1 (5.7, 6.5)

6.3 (5.9, 6.6)

2.3 (2.1, 2.6)*

3.9 (3.3, 4.4)

5.1 (4.7, 5.5)*

DAS28-ESR objective component

3.0 (2.9, 3.2)

3.0 (2.7, 3.2)

3.4 (3.2, 3.6)*

1.7 (1.5, 1.8)

1.7 (1.5, 1.9)

2.8 (2.7, 3.0)*

DAS28-ESR subjective component

2.1 (1.9, 2.3)*

3.1 (2.9, 3.4)

2.9 (2.7, 3.1)

0.6 (0.5, 0.8)*

2.1 (1.8, 2.5)

2.3 (2.0, 2.6)

DAS28-P

0.40 (0.38, 0.43)*

0.52 (0.50, 0.55)

0.45 (0.43, 0.48)*

0.23 (0.19, 0.28)*

0.56 (0.52, 0.59)

0.43 (0.39, 0.47)*

mHAQ

0.61 (0.49, 0.73)*

0.91 (0.75, 1.07)

0.82 (0.64, 0.99)

0.11 (0.04, 0.18)*

0.47 (0.25, 0.67)

0.48 (0.32, 0.63)

Fatigue

36.1(30.6, 41.6)*

66.7 (58.7, 74.6)

53.7 (45.1, 62.2)*

18.9 (12.7, 25.1)*

44.6 (35.0, 54.1)

48.3 (39.4, 57.1)

Helplessness

13.0 (11.8, 14.3)*

16.1 (14.2, 17.9)

15.4 (13.7, 17.1)

8.6 (7.6, 9.6)*

13.0 (11.4, 14.6)

13.0 (11.4, 14.7)

SF-36

 Physical component score

37.5 (35.1, 39.9)*

32.1 (29.9, 34.3)

33.5 (30.6, 36.4)

47.6 (45.3, 50.0)*

38.5 (35.4, 41.6)

35.7 (32.9, 38.6)

 Mental component score

43.5 (40.8, 46.3)*

35.3 (33.3, 38.3)

37.0 (32.8, 41.2)

48.4 (40.8, 46.3)*

41.4 (37.6, 45.1)

40.1 (35.9, 44.4)

Methotrexate dose

12.8 (14.7, 20.9)*

18.5 (15.5, 21.5)

18.6 (15.3, 21.8)

Leflunomide use (%)

4% (0, 10)*

16% (2, 30)

40% (21, 59)

Cumulative glucocorticoid dose, mg: median (IQR)

171 (100, 250)

199 (150, 450)

297 (211, 484)

Total erosion score

0.5 (0.3, 0.8)

0.5 (0.1, 1.0)

1.0 (0.3, 1.7)

1.2 (0.6, 1.7)

0.9 (0.2, 1.7)

2.4 (1.1, 3.6)*